Our research delves into a variety of critical health issues, with a focus on innovative approaches and comprehensive analyses to improve patient outcomes. We have explored peripheral inflammatory and metabolic markers as potential biomarkers in treatment-resistant schizophrenia, providing insights from a Qatari cohort. Our work addresses the challenges in managing nonmotor symptoms of Parkinson's disease in low-resourced settings, highlighting the unavailability of newer drugs. We have conducted a systematic review and meta-analysis on prenatal psychological distress and its impact on 11β-HSD2 gene expression in human placentas, offering valuable insights into maternal and fetal health.
Our studies on posterior circulation ischemic stroke provide detailed insights into its incidence, clinical features, and outcomes, utilizing data from a large multiethnic stroke database. The QPGx-CARES initiative focuses on enhancing pharmacogenetics clinical applications and research strategies in Qatar. We have assessed the predictive value of the neutrophil percentage to albumin ratio for ICU admission in ischemic stroke patients, and reviewed the history and challenges of clozapine utilization in the Arab world.
Our research also includes functional priorities of individuals with spinal cord injury from a Saudi Arabian perspective, and the impact of clinical versus fixed warfarin dosing on the quality of anticoagulation, as demonstrated in the ClinFix trial. We have identified differentially expressed miRNA profiles in serum-derived extracellular vesicles from patients with acute ischemic stroke, and developed TB-CXRNet, a technique for detecting tuberculosis and drug-resistant tuberculosis using chest X-ray images.
We have delineated the molecular mechanisms of hippocampal neurotoxicity induced by chronic administration of synthetic cannabinoid AB-FUBINACA in mice, and utilized genomic insights and advanced machine learning to characterize autism spectrum disorder biomarkers and genetic interactions. Our early warning tool for predicting mortality risk in COVID-19 patients leverages machine learning to enhance clinical decision-making.
Our research on the role of religiosity types in the phenomenology of hallucinations provides a large cross-sectional community-based study in a predominantly Muslim society. We have investigated the anti-cancer activity of bortezomib through the regulation of the Skp2/p53 axis in non-melanoma skin cancer cells and C. elegans, and conducted a clinical trial on the pharmacokinetics of single-dose rivaroxaban in obese versus non-obese subjects.
Through these diverse studies, we aim to contribute valuable insights and practical solutions to enhance health outcomes and patient care globally.
Some of our recent studies
- Phan, T. H. G., Paliogiannis, P., Nasrallah, G. K., Giordo, R., Eid, A. H., Fois, A. G., Zinellu, A., Mangoni, A. A., & Pintus, G. (2021). Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. Cellular and Molecular Life Sciences, 78(5), 2031-2057. https://doi.org/10.1007/s00018-020-03693-7
- NCD Risk Factor Collaboration (NCD-RisC). (2021). Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. eLife, 10, e60060. https://doi.org/10.7554/eLife.60060
- Chowdhury, M. E. H., Rahman, T., Khandakar, A., Al-Madeed, S., Zughaier, S. M., Doi, S. A. R., Hassen, H., & Islam, M. T. (2024). An Early Warning Tool for Predicting Mortality Risk of COVID-19 Patients Using Machine Learning. Cognitive Computation, 16, 1778-1793. https://doi.org/10.1007/s12559-020-09812-7
- Çakır, I., Pan, P. L., Hadley, C. K., El-Gamal, A., Fadel, A., Elsayegh, D., Mohamed, O., Rizk, N. M., & Ghamari-Langroudi, M. (2022). Sulforaphane reduces obesity by reversing leptin resistance. eLife, 11, e67368. https://doi.org/10.7554/eLife.67368
- Shaito, A., Al-Mansoob, M., Ahmad, S. M. S., Haider, M. Z., Eid, A. H., Posadino, A. M., Pintus, G., & Giordo, R. (2023). Resveratrol-Mediated Regulation of Mitochondria Biogenesis-associated Pathways in Neurodegenerative Diseases: Molecular Insights and Potential Therapeutic Applications. Current Neuropharmacology, 21(5), 1184-1201. https://doi.org/10.2174/1570159x20666221012122855
- Majbour, N. K., Abdi, I. Y., Dakna, M., Wicke, T., Lang, E., Moussa, H. Y. A., Thomas, M. A., Trenkwalder, C., Safieh-Garabedian, B., Tokuda, T., Mollenhauer, B., & El-Agnaf, O. (2021). Cerebrospinal α-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort. Movement Disorders, 36(5), 1106-1115. https://doi.org/10.1002/mds.28611
- Xu, C., Furuya-Kanamori, L., Kwong, J. S. W., Li, S., Liu, Y., & Doi, S. A. (2021). Methodological issues of systematic reviews and meta-analyses in the field of sleep medicine: A meta-epidemiological study. Sleep Medicine Reviews, 57, 101434. https://doi.org/10.1016/j.smrv.2021.101434
- Rahmani, J., Roudsari, A. H., Bawadi, H., Clark, C., Ryan, P. M., Salehisahlabadi, A., Rahimi Sakak, F., & Razaz, J. M. (2022). Body mass index and risk of Parkinson, Alzheimer, Dementia, and Dementia mortality: a systematic review and dose–response meta-analysis of cohort studies among 5 million participants. Nutritional Neuroscience, 25(3), 423-431. https://doi.org/10.1080/1028415x.2020.1758888
- Constantinides, V. C., Majbour, N. K., Paraskevas, G. P., Abdi, I., Safieh-Garabedian, B., Stefanis, L., El-Agnaf, O. M., & Kapaki, E. (2021). Cerebrospinal fluid α-synuclein species in cognitive and movements disorders. Brain Sciences, 11(1), 119. https://doi.org/10.3390/brainsci11010119
- Kim, B. S., Kim, S. J., Lee, J. Y., & Kim, H. J. (2023). Innate immune regulates cutaneous sensory IL-13 receptor alpha 2 to promote atopic dermatitis. Journal of Allergy and Clinical Immunology, 151(2), 456-467. https://doi.org/10.1016/j.jaci.2022.09.012
Contact Us Email:h.research@qu.edu.qa